432 related articles for article (PubMed ID: 2058180)
1. The disposition of [14C]-labelled benazepril HCl in normal adult volunteers after single and repeated oral dose.
Waldmeier F; Kaiser G; Ackermann R; Faigle JW; Wagner J; Barner A; Lasseter KC
Xenobiotica; 1991 Feb; 21(2):251-61. PubMed ID: 2058180
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic/pharmacodynamic modelling of the disposition and effect of benazepril and benazeprilat in cats.
King JN; Maurer M; Toutain PL
J Vet Pharmacol Ther; 2003 Jun; 26(3):213-24. PubMed ID: 12755906
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of the active metabolite of benazepril, benazeprilat, and inhibition of plasma angiotensin-converting enzyme activity after single and repeated administrations to dogs.
King JN; Mauron C; Kaiser G
Am J Vet Res; 1995 Dec; 56(12):1620-8. PubMed ID: 8599524
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of the angiotensin converting enzyme inhibitor benazepril.HCl (CGS 14 824 A) in healthy volunteers after single and repeated administration.
Kaiser G; Ackermann R; Brechbühler S; Dieterle W
Biopharm Drug Dispos; 1989; 10(4):365-76. PubMed ID: 2758102
[TBL] [Abstract][Full Text] [Related]
5. Plasma angiotensin converting enzyme activity and pharmacokinetics of benazepril and benazeprilat in cats after single and repeated oral administration of benazepril.HCl.
King JN; Humbert-Droz E; Maurer M
J Vet Pharmacol Ther; 1999 Dec; 22(6):360-7. PubMed ID: 10651464
[TBL] [Abstract][Full Text] [Related]
6. Disposition of [14C]-benazepril hydrochloride in rat, dog and baboon. Absorption, distribution, kinetics, biotransformation and excretion.
Waldmeier F; Schmid K
Arzneimittelforschung; 1989 Jan; 39(1):62-7. PubMed ID: 2719745
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of the angiotensin-converting-enzyme inhibitor, benazepril, and its active metabolite, benazeprilat, in dog.
King JN; Maurer M; Morrison CA; Mauron C; Kaiser G
Xenobiotica; 1997 Aug; 27(8):819-29. PubMed ID: 9293618
[TBL] [Abstract][Full Text] [Related]
8. The influence of hepatic cirrhosis on the pharmacokinetics of benazepril hydrochloride.
Kaiser G; Ackermann R; Gschwind HP; James IM; Sprengers D; McIntyre N; Defalco A; Holmes IB
Biopharm Drug Dispos; 1990 Dec; 11(9):753-64. PubMed ID: 2271751
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of the ace inhibitor benazepril hydrochloride in the elderly.
Kaiser G; Ackermann R; Dieterle W; Durnin CJ; McEwen J; Ghose K; Richens A; Holmes IB
Eur J Clin Pharmacol; 1990; 38(4):379-85. PubMed ID: 2344861
[TBL] [Abstract][Full Text] [Related]
10. The disposition of radioactivity after administration of the anthelminthic methyl-14C-5-cyclopropylcarbonyl-2-benzimidazole carbamate (ciclobendazole) to rats and dogs.
Brodie RR; Mayo BC; Chasseaud LF; Hawkins DR
Arzneimittelforschung; 1977; 27(3):593-8. PubMed ID: 577426
[TBL] [Abstract][Full Text] [Related]
11. Benazeprilat disposition and effect in dogs revisited with a pharmacokinetic/pharmacodynamic modeling approach.
Toutain PL; Lefebvre HP; King JN
J Pharmacol Exp Ther; 2000 Mar; 292(3):1087-93. PubMed ID: 10688627
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic/pharmacodynamic modeling of benazepril and benazeprilat after administration of intravenous and oral doses of benazepril in healthy horses.
Serrano-Rodríguez JM; Gómez-Díez M; Esgueva M; Castejón-Riber C; Mena-Bravo A; Priego-Capote F; Ayala N; Caballero JMS; Muñoz A
Res Vet Sci; 2017 Oct; 114():117-122. PubMed ID: 28371693
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of benazepril hydrochloride in patients with major proteinuria.
Schweizer C; Kaiser G; Dieterle W; Mann J
Eur J Clin Pharmacol; 1993; 44(5):463-6. PubMed ID: 8359184
[TBL] [Abstract][Full Text] [Related]
14. Plasma concentrations of an angiotensin-converting enzyme inhibitor, benazepril, and its active metabolite, benazeprilat, after repeated administrations of benazepril in dogs with experimental kidney impairment.
Kitagawa H; Eguchi T; Kitoh K; Ohba Y; Kondo M; Nakano M; Sasaki Y
J Vet Med Sci; 2000 Feb; 62(2):179-85. PubMed ID: 10720188
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of 14C-radioactivity after oral intake of a single dose of 14C-labeled fampridine (4-aminopyridine) in healthy volunteers.
Blight AR; Henney HR
Clin Ther; 2009 Feb; 31(2):328-35. PubMed ID: 19302905
[TBL] [Abstract][Full Text] [Related]
16. Effect of renal insufficiency on the pharmacokinetics and pharmacodynamics of benazepril in cats.
King JN; Strehlau G; Wernsing J; Brown SA
J Vet Pharmacol Ther; 2002 Oct; 25(5):371-8. PubMed ID: 12423228
[TBL] [Abstract][Full Text] [Related]
17. Mass balance study of [14C]M100240, a dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, in healthy male subjects.
Shah B; Emmons G; Rohatagi S; Martin NE; Jensen BK
Am J Ther; 2003; 10(5):356-62. PubMed ID: 12975720
[TBL] [Abstract][Full Text] [Related]
18. The pharmacokinetics of benazepril relative to other ACE inhibitors.
Gengo FM; Brady E
Clin Cardiol; 1991 Aug; 14(8 Suppl 4):IV44-50; discussion IV51-5. PubMed ID: 1893642
[TBL] [Abstract][Full Text] [Related]
19. The absence of a pharmacokinetic interaction between aspirin and the angiotensin-converting enzyme inhibitor benazepril in healthy volunteers.
Sioufi A; Pommier F; Gauducheau N; Godbillon J; Choi L; John V
Biopharm Drug Dispos; 1994 Aug; 15(6):451-61. PubMed ID: 7993983
[TBL] [Abstract][Full Text] [Related]
20. Absorption, metabolism, and excretion of [14C]imidafenacin, a new compound for treatment of overactive bladder, after oral administration to healthy male subjects.
Ohmori S; Miura M; Toriumi C; Satoh Y; Ooie T
Drug Metab Dispos; 2007 Sep; 35(9):1624-33. PubMed ID: 17567733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
